---
title: "Vabysmo (faricimab-svoa), all indications: Specific populations questions"
description: "Specific populations questions on Vabysmo (faricimab-svoa) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Can Vabysmo be used during pregnancy? Can Vabysmo be used while breastfeeding? How long is contraception needed after the last Vabysmo dose? Does Vabysmo affect fertility? 3 further questions follow. 7 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/vabysmo/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa), all indications: Specific populations questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)  
Indication pages: [Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)

## Pregnancy and breastfeeding

<a id="vabysmo-pregnancy"></a>

### Can Vabysmo be used during pregnancy?

> “There are no adequate and well-controlled studies of VABYSMO administration in pregnant 
> women. 
>
> Administration of VABYSMO to pregnant monkeys throughout the period of organogenesis 
> resulted in an increased incidence of abortions at intravenous (IV) doses 158 times the human 
> exposure (based on Cmax) of the maximum recommended human dose [see Animal Data].  Based 
> on the mechanism of action of VEGF and Ang-2 inhibitors, there is a potential risk to female 
> reproductive capacity, and to embryo-fetal development. VABYSMO should not be used during 
> pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus.”

Source: [VABYSMO: Prescribing information, page 12, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=12)

<a id="vabysmo-breastfeeding"></a>

### Can Vabysmo be used while breastfeeding?

> “There is no information regarding the presence of faricimab in human milk, the effects of the 
> drug on the breastfed infant, or the effects of the drug on milk production. Many drugs are 
> transferred in human milk with the potential for absorption and adverse reactions in the breastfed 
> child.   
>
> The developmental and health benefits of breastfeeding should be considered along with the 
> mother’s clinical need for VABYSMO and any potential adverse effects on the breastfed child 
> from VABYSMO.”

Source: [VABYSMO: Prescribing information, page 13, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=13)

<a id="vabysmo-contraception"></a>

### How long is contraception needed after the last Vabysmo dose?

> “Females of reproductive potential are advised to use effective contraception prior to the initial 
> dose, during treatment and for at least 3 months following the last dose of VABYSMO.”

Source: [VABYSMO: Prescribing information, page 13, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=13)

## Specific populations

<a id="vabysmo-fertility"></a>

### Does Vabysmo affect fertility?

> “No studies on the effects of faricimab on human fertility have been conducted and it is not 
> known whether faricimab can affect reproduction capacity. Based on the mechanism of action, 
> treatment with VABYSMO may pose a risk to reproductive capacity.”

Source: [VABYSMO: Prescribing information, page 13, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=13)

<a id="vabysmo-older-adults"></a>

### Is Vabysmo safe for adults 65 and older?

> “In the six clinical studies, approximately 58% (1,496/2,571) of patients randomized to treatment 
> with VABYSMO were ≥ 65 years of age. No significant differences in efficacy or safety of 
> faricimab were seen with increasing age in these studies. No dose adjustment is required in 
> patients 65 years and above.”

Source: [VABYSMO: Prescribing information, page 13, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=13)

<a id="vabysmo-kidney-liver"></a>

### Does Vabysmo need a dose adjustment for kidney or liver problems?

> “The systemic pharmacokinetics of faricimab were not influenced by gender, race, or mild to 
> severe renal impairment (i.e., estimated normalized creatinine clearance by Cockroft-Gault 
> equation: 15 to 89 mL/min/1.73 m<sup>2</sup>). The effect of severe renal impairment or any degree of 
> hepatic impairment on the pharmacokinetics of VABYSMO is unknown. No special dosage 
> modification is required for any of the populations that have been studied (e.g., elderly, gender, 
> race).”

Source: [VABYSMO: Prescribing information, page 15, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=15)

## Pediatric use

<a id="vabysmo-children"></a>

### Is Vabysmo safe and effective for children?

> “The safety and efficacy of VABYSMO in pediatric patients have not been established.”

Source: [VABYSMO: Prescribing information, page 13, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=13)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): All indications](https://www.evicenter.com/medical-information/vabysmo)
- [Indication](https://www.evicenter.com/medical-information/vabysmo/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vabysmo/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/vabysmo/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/vabysmo/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vabysmo/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vabysmo/access-and-coverage)
